Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT.
Denmeade SR, et al. Among authors: dalrymple s.
Sci Transl Med. 2012 Jun 27;4(140):140ra86. doi: 10.1126/scitranslmed.3003886.
Sci Transl Med. 2012.
PMID: 22745436
Free PMC article.
Clinical Trial.